Bluebird forced to halt trials after a cancer-like case, pulls gene therapies from Europe following pricing backlash — shares slammed
Bluebird bio halted a trial for its gene therapy for a rare neurological disease after finding that the treatment likely caused a cancer-like condition in one patient, the company announced Monday.
A boy with cerebral adrenoleukodystrophy was diagnosed with myelodysplastic syndrome, a condition that can develop into leukemia, after receiving eli-cel, a gene therapy that the company has shown can often halt the fatal disorder and which they had planned to file for US approval later this year. Two other patients are also being monitored for similar symptoms, and the FDA has put a clinical hold on eli-cel trials.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,200+ biopharma pros reading Endpoints daily — and it's free.